Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $2.0 billion.

  • Teva Pharmaceutical Industries' Free Cash Flow rose 3994.45% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 2320.92%. This contributed to the annual value of $2.2 billion for FY2025, which is 2320.92% up from last year.
  • Teva Pharmaceutical Industries' Free Cash Flow amounted to $2.0 billion in Q4 2025, which was up 3994.45% from $233.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Free Cash Flow's 5-year high stood at $2.1 billion during Q4 2023, with a 5-year trough of -$555.0 million in Q1 2021.
  • In the last 5 years, Teva Pharmaceutical Industries' Free Cash Flow had a median value of $168.0 million in 2023 and averaged $353.3 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Free Cash Flow plummeted by 41355.93% in 2021, and later soared by 522500.0% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Free Cash Flow (Quarter) stood at $303.0 million in 2021, then skyrocketed by 174.26% to $831.0 million in 2022, then surged by 154.75% to $2.1 billion in 2023, then crashed by 31.88% to $1.4 billion in 2024, then skyrocketed by 39.94% to $2.0 billion in 2025.
  • Its Free Cash Flow was $2.0 billion in Q4 2025, compared to $233.0 million in Q3 2025 and $131.0 million in Q2 2025.